Nanostart Subsidiary MagForce Nanotechnologies AG Expands Management Team
Nanostart Subsidiary MagForce Nanotechnologies AG Expands Management Team
"important step in the transformation into a commercial company"
Therapy expected to become available in the first quarter of 2011
at leading German cancer centers
Additional commercialization positions
Nov. 15, 2010 (Business Wire) -- Nanostart subsidiary MagForce Nanotechnologies AG (FSE:MF6), a leader in the area of nanotechnology-based cancer treatment, announced today the expansion of its management team. The new positions will support both the upcoming product launch of the company’s EU approved therapy for the treatment of brain tumors and the further development of its Nano-Cancer® therapy in additional cancer indications. MagForce expects its Nano-Cancer®-therapy will become available at several leading German cancer centers in the first quarter of 2011.
“Filling these key company positions is an important step in the transformation of the company from a research and development only business into a commercial company. Additional hiring for the sales and marketing team will be completed by the end of the year,” said Dr. Peter Heinrich, CEO of MagForce. “I am extremely pleased to welcome Dr. Christoph Rehfuess, Dr. Dirk Kautz, Mr. Kajo Wiest, and Ms. Stacy Wiedenmann to MagForce. Furthermore, Dr. Hans Joachim Hutt is currently serving as a medical consultant. These individuals bring with them the experience and expertise to support MagForce as we build commercial infrastructures and medical networks.”
Dr. Christoph Rehfuess joins MagForce as Director of Intellectual Property. As a qualified European Patent attorney with twelve years of management experience in the Biotech intellectual property field at MediGene AG, he will be responsible for patents, trademarks, and technical contracts.
Dr. Dirk Kautz joins MagForce as Director of Business/Corporate Development and will support the Management Board in strategic planning. Prior to joining MagForce, he worked for more than 13 years in the medical devices industry, holding management positions in marketing and corporate development at, amongst others, Nihon Kohden and Biotronik.
Kajo Wiest joins as Director of Finance & Controlling and brings with him more than ten years of finance and controlling experience at Jerini AG. During his time at Jerini, he was responsible for the establishment of controlling structures as well as supporting the company’s IPO and the sale of its wholly-owned subsidiary JPT, where he served as Finance Manager last year.
Stacy Wiedenmann joins the company as Director of Investor Relations & Corporate Communications and brings with her over ten years of experience, including her experience at Jerini AG where she headed the same areas from their IPO through their acquisition.
Dr. Hans Joachim Hutt MD, PhD will support the company in the area of medical affairs. His medical training and over 20 years of experience at leading pharmaceutical companies, including Boehringer Ingelheim, Sanofi, Bristol-Myers Squibb, and Sanofi Pasteur MSD, will help MagForce establish commercial networks and expand its therapeutic applications.
About Nanostart:
Nanostart AG, headquartered in the German financial capital of Frankfurt, is the world’s leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. The company provides venture capital financing for nanotechnology companies in various growth phases with a focus on innovation-driven industries of the future such as cleantech, life sciences and IT/electronics. Through its subsidiary and venture capital fund in Singapore, Nanostart is proud to be the investment partner of the Singaporean government. For further information, please visit www.nanostart.de.
About MagForce Nanotechnologies:
MagForce Nanotechnologies AG is a world-leading company in the area of nanotechnology-based cancer treatment. The proprietary procedure which it has developed, Nano-Cancer® therapy, enables the targeted treatment of solid tumors through the intratumoral release of heat from magnetic nanoparticles. Its products used in the therapy, NanoTherm® and NanoActivator®, have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. For further information, please visit www.magforce.com.
Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia or Japan.
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
e-mail: presse@nanostart.de
Source: Business Wire (November 15, 2010 - 6:25 AM EST)
News by QuoteMedia
www.quotemedia.com
AI
